the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry

A Clinical Study on the Exploration of MTAP Deletion in Osteosarcoma Specimens by Immunohistochemistry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07593573

Enrollment

100

Registered

2026-05-18

Start date

2025-12-15

Completion date

2026-12-14

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunohistochemistry, MTAP Deletion, Osteosarcoma

Brief summary

MTAP deletion frequently occurs in osteosarcoma, and PRMT5 has been identified as a synthetic lethal target for cancers with homozygous deletion of the MTAP gene, making it a promising target for anti-tumor drug development.This study aims to evaluate the overall status of MTAP deficiency in the tissues of osteosarcoma patients and its correlation with clinical features such as metastasis and immune subtypes by examining the MTAP protein expression levels in previous histological samples of the patients and combining this with their clinicopathological data.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. advanced recurrent and refractory osteosarcoma confirmed by histopathology; 2. initial treatment in the Orthopedic/Oncology Departments of Peking University People's Hospital or Peking University Shougang Hospital; 3. progression less than 6 months after first-line chemotherapy with a combination of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide (first-line chemotherapy); 4. measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1) ; 5. Eastern Cooperative Oncology Group performance status ≤ 1 ; 6. acceptable haematologic, hepatic, and renal function.

Exclusion criteria

1. those who had been previously treated with antiangiogenic TKIs and single IE chemotherapy; 2. those who had severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. These confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction\<50%, and hypertension that could not be well controlled with antihypertensive drugs.; 3. all patients were assessed by the sarcoma board including a thoracic surgeon with at least 10 years surgical experience. Patients with lung metastases only were carefully assessed for eligibility for metastasectomy, of whom those who were suitable for surgery were excluded from this study; 4. weight loss of 20% or more before illness; 5. brain or leptomeningeal metastasis; 6. surgical procedure or radiotherapy within 4 weeks of enrollment; 7. activegastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation; 8. proteinuria or hematuria, denutrition with albuminemia \<25 g/L; 9. women who were pregnant or breast feeding, other malignancy; 10. positive HBV/HCV/HIV serology, and known allergy to the experimental agents.

Design outcomes

Primary

Measure	Time frame	Description
Progression free survival	2 years	from the start of target treatment until disease progression or death, whichever came first.

Countries

China

Outcome results